Filtered By:
Infectious Disease: SARS
Vaccination: Cancer Vaccines
This page shows you your search results in order of date.
Order by Relevance | Date
Total 745 results found since Jan 2013.
Identification of γ-Fagarine as a novel antiviral agent against respiratory virus (hMPV) infection
In this study, we aim to investigate the effect of γ-Fagarine on hMPV infection and explore its underlying molecular mechanisms. Vero-E6 and 16HBE cells were used as cell models. Virus replication and microcosm character were explored in Vero-E6 cells. Then, the antiviral activities were investigated by quantitative real-time PCR (RT-qPCR), western blotting (WB), and indirect immunofluorescence assays (IFAs) in Vero-E6 and 16HBE. Potential mechanisms of γ-Fagarine related to HSPG and lysosome pH were assessed in 16HBE cells. Lastly, a virus-infected mouse model was established and antiviral assay in vivo was conducted. Î...
Source: Virus Research - September 21, 2023 Category: Virology Authors: Jinhua Li Yao Zhao Ying Dai Junning Zhao Source Type: research
Comparative effectiveness of mRNA-1273 and BNT162b2 COVID-19 vaccines in immunocompromised individuals: a systematic review and meta-analysis using the GRADE framework
ConclusionThis GRADE meta-analysis based on a large number of consistent observational studies showed that the mRNA-1273 COVID-19 vaccine is associated with improved clinical effectiveness in IC populations compared with BNT162b2.
Source: Frontiers in Immunology - September 12, 2023 Category: Allergy & Immunology Source Type: research
Stimuli-Responsive Hydrogel Microcapsules Harnessing the COVID-19 Immune Response for Cancer Therapeutics
We present the development of stimuli-responsive microcapsules, loaded with a viral immunogenetic agent, harnessing the immune response against the Coronavirus Disease 2019, COVID-19, to selectively attack liver cancer cells (hepatoma) or recognize breast cancer or hepatoma, by expression of green fluorescence protein, GFP. The pH-responsive microcapsules, modified with DNA-tetrahedra nanostructures, increased hepatoma permeation by 50%. Incorporation of a GFP-encoding lentivirus vector inside the tumor-targeting pH-stimulated miRNA-triggered and Alpha-fetoprotein-dictated microcapsules enables the demonstration of neoplas...
Source: Angewandte Chemie - September 7, 2023 Category: Chemistry Authors: Amit Fischer Avner Ehrlich Yevgeni Plotkin Yu Ouyang Klil Asulin Ioannidis Konstantinos Chunhai Fan Yaakov Nahmias Itamar Willner Source Type: research
A unique cytotoxic CD4 < sup > + < /sup > T cell-signature defines critical COVID-19
CONCLUSION: Highly activated and cytotoxic CD4+ T-cell responses may contribute to cell-mediated host tissue damage and progression of COVID-19. Induction of these potentially detrimental T-cell responses should be considered when developing and implementing effective COVID-19 control strategies.PMID:37645435 | PMC:PMC10461786 | DOI:10.1002/cti2.1463
Source: Cancer Control - August 30, 2023 Category: Cancer & Oncology Authors: Sarah Baird Caroline L Ashley Felix Marsh-Wakefield Sibel Alca Thomas M Ashhurst Angela L Ferguson Hannah Lukeman Claudio Counoupas Jeffrey J Post Pamela Konecny Adam Bartlett Marianne Martinello Rowena A Bull Andrew Lloyd Alice Grey Owen Hutchings Umaima Source Type: research
Plant Viruses as Adjuvants for Next-Generation Vaccines and Immunotherapy
Vaccines (Basel). 2023 Aug 16;11(8):1372. doi: 10.3390/vaccines11081372.ABSTRACTVaccines are the cornerstone of infectious disease control and prevention. The outbreak of SARS-CoV-2 has confirmed the urgent need for a new approach to the design of novel vaccines. Plant viruses and their derivatives are being used increasingly for the development of new medical and biotechnological applications, and this is reflected in a number of preclinical and clinical studies. Plant viruses have a unique combination of features (biosafety, low reactogenicity, inexpensiveness and ease of production, etc.), which determine their potentia...
Source: Cancer Control - August 26, 2023 Category: Cancer & Oncology Authors: Nikolai Nikitin Yuri Vasiliev Angelina Kovalenko Ekaterina Ryabchevskaya Olga Kondakova Ekaterina Evtushenko Olga Karpova Source Type: research
COVID-19 Vaccination Effectiveness in the General Population of an Italian Province: Two Years of Follow-Up
Vaccines (Basel). 2023 Aug 4;11(8):1325. doi: 10.3390/vaccines11081325.ABSTRACTWe carried out a cohort study on the overall population of the province of Pescara, Italy, to assess the real-world effectiveness of SARS-CoV-2 vaccination against infection, severe, or lethal COVID-19, two years after the start of the vaccination campaign. We included all the resident or domiciled subjects, and extracted the official demographic, vaccination, COVID-19, hospital and co-pay exemption datasets from 1 January 2021, up to 15 February 2023. Cox proportional hazards analyses were adjusted for gender, age, diabetes, hypertension, COPD,...
Source: Cancer Control - August 26, 2023 Category: Cancer & Oncology Authors: Annalisa Rosso Maria Elena Flacco Graziella Soldato Giuseppe Di Martino Cecilia Acuti Martellucci Roberto Carota Marco De Benedictis Graziano Di Marco Rossano Di Luzio Matteo Fiore Antonio Caponetti Lamberto Manzoli Source Type: research
mRNA vaccine in cancer therapy: Current advance and future outlook
Clin Transl Med. 2023 Aug;13(8):e1384. doi: 10.1002/ctm2.1384.ABSTRACTMessenger ribonucleic acid (mRNA) vaccines are a relatively new class of vaccines that have shown great promise in the immunotherapy of a wide variety of infectious diseases and cancer. In the past 2 years, SARS-CoV-2 mRNA vaccines have contributed tremendously against SARS-CoV2, which has prompted the arrival of the mRNA vaccine research boom, especially in the research of cancer vaccines. Compared with conventional cancer vaccines, mRNA vaccines have significant advantages, including efficient production of protective immune responses, relatively low s...
Source: Clinical Breast Cancer - August 24, 2023 Category: Cancer & Oncology Authors: Youhuai Li Mina Wang Xueqiang Peng Yingying Yang Qishuang Chen Jiaxing Liu Qing She Jichao Tan Chuyuan Lou Zehuan Liao Xuexin Li Source Type: research
Prior cycles of anti-CD20 antibodies affect antibody responses after repeated SARS-CoV-2 mRNA vaccination
CONCLUSIONThese results demonstrate that serial vaccination strategies can be effective for a subset of B cell-depleted patients.FUNDINGThe NIH (R25 NS079193, P01 AI073748, U24 AI11867, R01 AI22220, UM 1HG009390, P01 AI039671, P50 CA121974, R01 CA227473, U01CA260507, 75N93019C00065, K24 AG042489), NIH HIPC Consortium (U19 AI089992), the National Multiple Sclerosis Society (CA 1061-A-18, RG-1802-30153), the Nancy Taylor Foundation for Chronic Diseases, Erase MS, and the Claude D. Pepper Older Americans Independence Center at Yale (P30 AG21342).PMID:37606046 | DOI:10.1172/jci.insight.168102
Source: Cancer Control - August 22, 2023 Category: Cancer & Oncology Authors: Hiromitsu Asashima Dongjoo Kim Kaicheng Wang Nikhil Lele Nicholas C Buitrago-Pocasangre Rachel Lutz Isabella Cruz Khadir Raddassi William E Ruff Michael K Racke JoDell E Wilson Tara S Givens Alba Grifoni Daniela Weiskopf Alessandro Sette Steven H Kleinste Source Type: research
Reduced SARS-CoV-2 mRNA vaccine immunogenicity and protection in mice with diet-induced obesity and insulin resistance
CONCLUSION: We demonstrate impaired immunity following SARS-CoV-2 mRNA immunization in a murine model of comorbid T2DM and obesity, supporting the need for further research into the basis for impaired anti-SARS-CoV-2 immunity in T2DM and investigation of novel approaches to enhance vaccine immunogenicity among those with metabolic diseases.PMID:37595760 | DOI:10.1016/j.jaci.2023.06.031
Source: Clinical Lung Cancer - August 18, 2023 Category: Cancer & Oncology Authors: Timothy R O'Meara Etsuro Nanishi Marisa E McGrath Soumik Barman Danica Dong Carly Dillen Manisha Menon Hyuk-Soo Seo Sirano Dhe-Paganon Robert K Ernst Ofer Levy Matthew B Frieman David J Dowling Source Type: research
Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency
Nat Commun. 2023 Aug 18;14(1):5032. doi: 10.1038/s41467-023-40758-0.ABSTRACTT-cell immunity is central for control of COVID-19, particularly in patients incapable of mounting antibody responses. CoVac-1 is a peptide-based T-cell activator composed of SARS-CoV-2 epitopes with documented favorable safety profile and efficacy in terms of SARS-CoV-2-specific T-cell response. We here report a Phase I/II open-label trial (NCT04954469) in 54 patients with congenital or acquired B-cell deficiency receiving one subcutaneous CoVac-1 dose. Immunogenicity in terms of CoVac-1-induced T-cell responses and safety are the primary and seco...
Source: Cancer Control - August 18, 2023 Category: Cancer & Oncology Authors: Jonas S Heitmann Claudia Tandler Maddalena Marconato Annika Nelde Timorshah Habibzada Susanne M Rittig Christian M Tegeler Yacine Maringer Simon U Jaeger Monika Denk Marion Richter Melek T Oezbek Karl-Heinz Wiesm üller Jens Bauer Jonas Rieth Marcel Wacke Source Type: research
Reduced SARS-CoV-2 mRNA vaccine immunogenicity and protection in mice with diet-induced obesity and insulin resistance
CONCLUSION: We demonstrate impaired immunity following SARS-CoV-2 mRNA immunization in a murine model of comorbid T2DM and obesity, supporting the need for further research into the basis for impaired anti-SARS-CoV-2 immunity in T2DM and investigation of novel approaches to enhance vaccine immunogenicity among those with metabolic diseases.PMID:37595760 | DOI:10.1016/j.jaci.2023.06.031
Source: Clinical Lung Cancer - August 18, 2023 Category: Cancer & Oncology Authors: Timothy R O'Meara Etsuro Nanishi Marisa E McGrath Soumik Barman Danica Dong Carly Dillen Manisha Menon Hyuk-Soo Seo Sirano Dhe-Paganon Robert K Ernst Ofer Levy Matthew B Frieman David J Dowling Source Type: research
Influence of SARS-CoV-2 mRNA Vaccine Booster among Cancer Patients on Active Treatment Previously Immunized with Inactivated versus mRNA Vaccines: A Prospective Cohort Study
Vaccines (Basel). 2023 Jul 3;11(7):1193. doi: 10.3390/vaccines11071193.ABSTRACTCancer patients on chemotherapy have a lower immune response to SARS-CoV-2 vaccines. Therefore, through a prospective cohort study of patients with solid tumors receiving chemotherapy, we aimed to determine the immunogenicity of an mRNA vaccine booster (BNT162b2) among patients previously immunized with an inactivated (CoronaVac) or homologous (BNT162b2) SARS-CoV-2 vaccine. The primary outcome was the proportion of patients with anti-SARS-CoV-2 neutralizing antibody (NAb) seropositivity at 8-12 weeks post-booster. The secondary end points includ...
Source: Cancer Control - July 29, 2023 Category: Cancer & Oncology Authors: Sebasti án Mondaca Benjam Ãn Walbaum Nicole Le Corre Marcela Ferr és Alejandro Vald és Constanza Mart Ãnez-Valdebenito Cinthya Ruiz-Tagle Patricia Macanas-Pirard Patricio Ross Betzab é Cisternas Patricia P érez Olivia Cabrera Valentina Cerda Ivana Source Type: research
